Market
Will Daiichi Sankyo's stock price increase by more than 20% by March 31, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock market data from financial news platforms
Story
AstraZeneca and Daiichi Sankyo Win First U.S. Approval for Novel Breast Cancer Treatment; Stock Rises Most in Five Months
Jan 19, 2025, 05:37 PM
AstraZeneca and Daiichi Sankyo have received U.S. approval for a novel breast cancer treatment, marking a significant milestone in their efforts to establish the drug as a widely used option in oncology. This approval represents the first authorization for this closely monitored treatment, which has prompted a notable increase in Daiichi Sankyo's stock, rising the most in five months. The approval was confirmed by multiple sources, including the FDA and various news outlets.
View original story
Similar markets
Increase less than 5% • 25%
Increase by more than 10% • 25%
No increase or decrease • 25%
Increase by 5-10% • 25%
